<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04873752</url>
  </required_header>
  <id_info>
    <org_study_id>UDI-001-0555</org_study_id>
    <nct_id>NCT04873752</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety and Efficacy of UC-MSCs in Pediatric Patients With Cerebral Palsy</brief_title>
  <official_title>An Exploratory Study to Investigate the Safety and Efficacy of UC-MSCs in Pediatric Patients With Cerebral Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rohto Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rohto Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      UDI-001 is administered to pediatric patients with cerebral palsy attributed to&#xD;
      periventricular leukomalacia (PVL) multiple times to investigate its safety and efficacy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is the first study of UDI-001 to be administered to children. Pediatric patients with&#xD;
      cerebral palsy attributed to PVL are enrolled to the study and umbilical cord derived&#xD;
      mesenchymal stromal cells (UC-MSCs) are administered to those patients multiple times&#xD;
      intravenously. Safety and efficacy of UC-MSCs are evaluated for 52 weeks after the first&#xD;
      administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Adverse Event</measure>
    <time_frame>until Week 52</time_frame>
    <description>Adverse events which appear in the participants after the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gross Motor Function Measure Score (GMFM Score)</measure>
    <time_frame>baseline to Week 52</time_frame>
    <description>Difference and change in GMFM score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gross Motor Function Classification System (GMFCS)</measure>
    <time_frame>baseline to Week 52</time_frame>
    <description>Improvement rate of GMFCS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function Independence Measure for Children (WeeFIM)</measure>
    <time_frame>baseline to Week 52</time_frame>
    <description>Change in WeeFIM score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kyoto Scale of Psychological Development Test 2001 (KSPD)</measure>
    <time_frame>baseline to Week 52</time_frame>
    <description>Change in and Improvement rate of KSPD</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Cerebral Palsy</condition>
  <condition>Periventricular Leukomalacia</condition>
  <arm_group>
    <arm_group_label>UDI-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four cycles with 8 administrations</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UDI-001</intervention_name>
    <description>2.5 x 10^6 cells/kg of UDI-001 are administered intravenously. One cycle consists of twice a week administrations.</description>
    <arm_group_label>UDI-001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 12 months and &lt; 24 months corrected age at the time of informed consent&#xD;
&#xD;
          -  Diagnosed with cerebral palsy&#xD;
&#xD;
          -  Diagnosed with PVL&#xD;
&#xD;
          -  GMFCS level between II and IV&#xD;
&#xD;
          -  Able to obtain written informed consent from parents (legal representative)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of progressive neurological disease&#xD;
&#xD;
          -  Presence of congenital anomaly&#xD;
&#xD;
          -  Diagnosed with Grade 3 or more severe intraventricular hemorrhage&#xD;
&#xD;
          -  Body weight &lt; 5kg&#xD;
&#xD;
          -  Profound intellectual disorder&#xD;
&#xD;
          -  Complication of serious infection such as sepsis&#xD;
&#xD;
          -  Requirement of mechanical ventilation&#xD;
&#xD;
          -  Complication of serious organ failure such as kidney, liver or heart diseases or&#xD;
             others and considered to be inappropriate&#xD;
&#xD;
          -  Diagnosed with or suspected of hypsarrhythmia&#xD;
&#xD;
          -  Positive for HBV, HCV, HIV or HTLV-1&#xD;
&#xD;
          -  Patients who have received cell therapy&#xD;
&#xD;
          -  Patients who have undergone selective dorsal rhizotomy or received botulinum toxin&#xD;
             products within a certain period of time&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sumito Okawa</last_name>
    <role>Study Director</role>
    <affiliation>Rohto Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ROHTO Pharmaceutical Co., Ltd.</last_name>
    <phone>+81-3-6823-6014</phone>
    <email>UDI-001_CTR@rohto.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Palsy</mesh_term>
    <mesh_term>Leukomalacia, Periventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

